Targeted-release budesonide (Kinpeygo, Genus Pharmaceuticals Holdings Ltd. [trading as STADA]) is indicated for 'the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.8 g/gram)'.
The dosage schedule is available in the summary of product characteristics for targeted-release budesonide (PDF only).
The list price of targeted-release budesonide is £4,681.24 for a 120‑pack of 4‑mg modified-release hard capsules.
The company has a commercial arrangement. This makes targeted-release budesonide available to the NHS with a discount. The size of the discount is commercial in confidence.
For information, the Carbon Reduction Plan for UK carbon emissions is published on STADA Thornton & Ross's page on its Values and Responsibilities.